Cationic nanoglycolipidic particles as vector and adjuvant for the study of the immunogenicity of SIV Nef protein

International Journal of Pharmaceutics

Volumn 423, Issue 1, 2012, Pages 116-123

  Haij, Nawal Ben ^a   Mzoughi, Olfa ^a   Plans, Rémi ^a   Bahraoui, Elmostafa ^a  

^a UNIVERSITÉ PAUL SABATIER   (France)

Author keywords

Adjuvant; Antibodies; HIV 1; Immunogenicity; Nanoparticles; Nef

Indexed keywords

ANTIGEN; FREUND ADJUVANT; GLUTATHIONE TRANSFERASE; GLYCOLIPID; IMMUNOGLOBULIN CLASS; IMMUNOGLOBULIN G1; MURAMYL DIPEPTIDE; NEF PROTEIN; RECOMBINANT VACCINE; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE;

ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ANTIBODY TITER; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN STABILITY; TH2 CELL;

1,2-DIPALMITOYLPHOSPHATIDYLCHOLINE; ACETYLMURAMYL-ALANYL-ISOGLUTAMINE; ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES; CATIONS; CHOLESTEROL; FEMALE; FREUND'S ADJUVANT; GLUTATHIONE TRANSFERASE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN ISOTYPES; LIPIDS; MICE; MICE, INBRED BALB C; NANOPARTICLES; POLYSACCHARIDES; RECOMBINANT FUSION PROTEINS; SAIDS VACCINES; VACCINATION; VIRAL REGULATORY AND ACCESSORY PROTEINS;

EID: 84855780759     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2011.06.049     Document Type: Conference Paper

References (52)

1. T.W. Baba, V. Liska, A.H. Khimani, N.B. Ray, P.J. Dailey, D. Penninck, R. Bronson, M.F. Greene, H.M. McClure, L.N. Martin, and R.M. Ruprecht Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques Nat. Med. 5 1999 194 203 (Pubitemid 29068527)
2. A.S. Baur, E.T. Sawai, P. Dazin, W.J. Fantl, C. Cheng-Mayer, and B.M. Peterlin HIV-1 Nef leads to inhibition or activation of T cells depending on its intracellular localization Immunity 1 1994 373 384
3. R.E. Benson, A. Sanfridson, J.S. Ottinger, C. Doyle, and B.R. Cullen Downregulation of cell-surface CD4 expression by simian immunodeficiency virus Nef prevents viral super infection J. Exp. Med. 177 1993 1561 1566 (Pubitemid 23146122)
4. M. Berton, S. Sixou, R. Kravtzoff, C. Dartigues, L. Imbertie, C. Allal, and G. Favre Improved oligonucleotide uptake and stability by a new drug carrier, the SupraMolecular Bio Vector (SMBV) Biochim. Biophys. Acta 1355 1997 7 19 (Pubitemid 27043020)
5. M. Bomsel, D. Tudor, A.S. Drillet, A. Alfsen, Y. Ganor, M.G. Roger, N. Mouz, M. Amacker, A. Chalifour, L. Diomede, G. Devillier, Z. Cong, Q. Wei, H. Gao, C. Qin, G.B. Yang, R. Zurbriggen, L. Lopalco, and S. Fleury Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges Immunity 34 2011 269 280
6. S.P. Buchbinder, D.V. Mehrotra, A. Duerr, D.W. Fitzgerald, R. Mogg, D. Li, P.B. Gilbert, J.R. Lama, M. Marmor, C. Del Rio, M.J. McElrath, D.R. Casimiro, K.M. Gottesdiener, J.A. Chodakewitz, L. Corey, and M.N. Robertson Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial Lancet 372 2008 1881 1893
7. L. Buonaguro, M.L. Tornesello, and F.M. Buonaguro Virus-like particles as particulate vaccines Curr. HIV Res. 8 2010 299 309
8. N. Castignolles, S. Morgeaux, C. Gontier-Jallet, D. Samain, D. Betbeder, and P. Perrin A new family of carriers (biovectors) enhances the immunogenicity of rabies antigens Vaccine 14 1996 1353 1360 (Pubitemid 27008197)
9. N. Cazeaux, Y. Bennasser, P.L. Vidal, Z. Li, D. Paulin, and E. Bahraoui Comparative study of immune responses induced after immunization with plasmids encoding the HIV-1 Nef protein under the control of the CMV-IE or the muscle-specific desmin promoter Vaccine 20 2002 3322 3331 (Pubitemid 35245816)
10. L. Chakrabarti, V. Baptiste, E. Khatissian, M.C. Cumont, A.M. Aubertin, L. Montagnier, and B. Hurtrel Limited viral spread and rapid immune response in lymph nodes of macaques inoculated with attenuated simian immunodeficiency virus Virology 213 1995 535 548
11. J. Chang, Y. Jallouli, M. Kroubi, X.B. Yuan, W. Feng, C.S. Kang, P.Y. Pu, and D. Betbeder Characterization of endocytosis of transferrin-coated PLGA nanoparticles by the blood-brain barrier Int. J. Pharm. 379 2009 285 292
12. M.Y. Chowers, C.A. Spina, T.J. Kwoh, N.J. Fitch, D.D. Richman, and J.C. Guatelli Optimal infectivity in vitro of human immunodeficiency virus type 1 requires an intact nef gene J. Virol. 68 1994 2906 2914 (Pubitemid 24129738)
13. R.L. Coffman, A. Sher, and R.A. Seder Vaccine adjuvants: putting innate immunity to work Immunity 33 2010 492 503
14. Y. Collette, C. Mawas, and D. Olive Evidence for intact CD28 signaling in T cell hyporesponsiveness induced by the HIV-1 nef gene Eur. J. Immunol. 26 1996 1788 1793 (Pubitemid 26283152)
15. K.L. Collins, B.K. Chen, S.A. Kalams, B.D. Walker, and D. Baltimore HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes Nature 391 1998 397 401 (Pubitemid 28093515)
16. M.D. Daniel, F. Kirchhoff, S.C. Czajak, P.K. Sehgal, and R.C. Desrosiers Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene Science 258 1992 1938 1941 (Pubitemid 23026733)
17. I. De Miguel, L. Imbertie, V. Rieumajou, M. Major, R. Kravtzoff, and D. Betbeder Proofs of the structure of lipid coated nanoparticles (SMBV) used as drug carriers Pharm. Res. 17 2000 817 824 (Pubitemid 30666962)
18. S.K. De, and J.W. Marsh HIV-1 Nef inhibits a common activation pathway in NIH-3T3 cells J. Biol. Chem. 269 1994 6656 6660 (Pubitemid 24191050)
19. N.J. Deacon, A. Tsykin, A. Solomon, K. Smith, M. Ludford-Menting, D.J. Hooker, D.A. McPhee, A.L. Greenway, A. Ellett, C. Chatfield, V.A. Lawson, S. Crowe, A. Maerz, S. Sonza, J. Learmont, J.S. Sullivan, A. Cunningham, D. Dwyer, D. Dowton, and J. Mills Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients Science 270 1995 988 991
20. A. Debin, R. Kravtzoff, J.V. Santiago, L. Cazales, S. Sperandio, K. Melber, Z. Janowicz, D. Betbeder, and M. Moynier Intranasal immunization with recombinant antigens associated with new cationic particles induces strong mucosal as well as systemic antibody and CTL responses Vaccine 20 2002 2752 2763 (Pubitemid 34601001)
21. C.Y. Dombu, M. Kroubi, R. Zibouche, R. Matran, and D. Betbeder Characterization of endocytosis and exocytosis of cationic nanoparticles in airway epithelium cells Nanotechnology 21 2010 355102
22. O.T. Fackler, A. Alcover, and O. Schwartz Modulation of the immunological synapse: a key to HIV-1 pathogenesis? Nat. Rev. Immunol. 7 2007 310 317 (Pubitemid 46480952)
23. J.L. Foster, and J.V. Garcia HIV-1 Nef: at the crossroads Retrovirology 5 2008 84
24. G. Franchini, M. Robert-Guroff, J. Ghrayeb, N.T. Chang, and F. Wong-Staal Cytoplasmic localization of the HTLV-III 3' orf protein in cultured T cells Virology 155 1986 593 599 (Pubitemid 17226262)
25. J.V. Garcia, and A.D. Miller Serine phosphorylation-independent downregulation of cell-surface CD4 by nef Nature 350 1991 508 511 (Pubitemid 21912265)
26. J.M. Greene, J.J. Lhost, B.J. Burwitz, M.L. Budde, C.E. Macnair, M.K. Weiker, E. Gostick, T.C. Friedrich, K.W. Broman, D.A. Price, S.L. O'Connor, and D.H. O'Connor Extralymphoid CD8+ T cells resident in tissue from simian immunodeficiency virus SIVmac239{Delta}nef-vaccinated macaques suppress SIVmac239 replication ex vivo J. Virol. 84 2010 3362 3372
27. B. Guy, M.P. Kieny, Y. Riviere, C. Le Peuch, K. Dott, M. Girard, L. Montagnier, and J.P. Lecocq HIV F/3' orf encodes a phosphorylated GTP-binding protein resembling an oncogene product Nature 330 1987 266 269
28. B. Heurtault, B. Frisch, and F. Pons Liposomes as delivery systems for nasal vaccination: strategies and outcomes Expert Opin. Drug. Deliv. 7 2010 829 844
29. A. Jere, M. Fujita, A. Adachi, and M. Nomaguchi Role of HIV-1 Nef protein for virus replication in vitro Microbes Infect. 12 2010 65 70
30. J. Kaminchik, R. Margalit, S. Yaish, H. Drummer, B. Amit, N. Sarver, M. Gorecki, and A. Panet Cellular distribution of HIV type 1 Nef protein: identification of domains in Nef required for association with membrane and detergent-insoluble cellular matrix AIDS Res. Hum. Retroviruses 10 1994 1003 1010 (Pubitemid 24279172)
31. T. Kawai, and S. Akira The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors Nat. Immunol. 11 2010 373 384
32. H.W. Kestler 3rd, D.J. Ringler, K. Mori, D.L. Panicali, P.K. Sehgal, M.D. Daniel, and R.C. Desrosiers Importance of the nef gene for maintenance of high virus loads and for development of AIDS Cell 65 1991 651 662
33. M. Major, E. Prieur, J.F. Tocanne, D. Betbeder, and A.M. Sautereau Characterization and phase behaviour of phospholipid bilayers adsorbed on spherical polysaccharidic nanoparticles Biochim. Biophys. Acta 1327 1997 32 40 (Pubitemid 27283396)
34. R. Mariani, F. Kirchhoff, T.C. Greenough, J.L. Sullivan, R.C. Desrosiers, and J. Skowronski High frequency of defective nef alleles in a long-term survivor with nonprogressive human immunodeficiency virus type 1 infection J. Virol. 70 1996 7752 7764 (Pubitemid 26339081)
35. M.J. McElrath, S.C. De Rosa, Z. Moodie, S. Dubey, L. Kierstead, H. Janes, O.D. Defawe, D.K. Carter, J. Hural, R. Akondy, S.P. Buchbinder, M.N. Robertson, D.V. Mehrotra, S.G. Self, L. Corey, J.W. Shiver, and D.R. Casimiro HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis Lancet 372 2008 1894 1905
36. M.J. McElrath, and B.F. Haynes Induction of immunity to human immunodeficiency virus type-1 by vaccination Immunity 33 2010 542 554
37. M.D. Miller, M.T. Warmerdam, I. Gaston, W.C. Greene, and M.B. Feinberg The human immunodeficiency virus-1 nef gene product: a positive factor for viral infection and replication in primary lymphocytes and macrophages J. Exp. Med. 179 1994 101 113 (Pubitemid 24012975)
38. C. Moureau, P.L. Vidal, Y. Bennasser, M. Moynier, Y. Nicaise, M. Aussillous, S. Barthelemy, L. Montagnier, and E. Bahraoui Characterization of humoral and cellular immune responses in mice induced by immunization with HIV-1 Nef regulatory protein encapsulated in poly(DL-lactide-co-glycolide) microparticles Mol. Immunol. 38 2002 607 618 (Pubitemid 34131584)
39. C.M. Noviello, S. Benichou, and J.C. Guatelli Cooperative binding of the class I major histocompatibility complex cytoplasmic domain and human immunodeficiency virus type 1 Nef to the endosomal AP-1 complex via its mu subunit J. Virol. 82 2008 1249 1258
40. K. Otake, Y. Fujii, T. Nakaya, Y. Nishino, Q. Zhong, K. Fujinaga, M. Kameoka, K. Ohki, and K. Ikuta The carboxyl-terminal region of HIV-1 Nef protein is a cell surface domain that can interact with CD4+ T cells J. Immunol. 153 1994 5826 5837 (Pubitemid 24377719)
41. P. Pitisuttithum, P. Gilbert, M. Gurwith, W. Heyward, M. Martin, F. van Griensven, D. Hu, J.W. Tappero, and K. Choopanya Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand J. Infect. Dis. 194 2006 1661 1671 (Pubitemid 44901996)
42. E. Prieur, D. Betbeder, F. Niedergang, M. Major, A. Alcover, J.L. Davignon, and C. Davrinche Combination of human cytomegalovirus recombinant immediate-early protein (IE1) with 80 nm cationic biovectors: protection from proteolysis and potentiation of presentation to CD4+ T-cell clones in vitro Vaccine 14 1996 511 520
43. A.D. Raymond, T.C. Campbell-Sims, M. Khan, M. Lang, M.B. Huang, V.C. Bond, and M.D. Powell HIV Type 1 Nef is released from infected cells in CD45(+) microvesicles and is present in the plasma of HIV-infected individuals AIDS Res. Hum. Retroviruses 27 2011 167 178
44. S. Rerks-Ngarm, P. Pitisuttithum, S. Nitayaphan, J. Kaewkungwal, J. Chiu, R. Paris, N. Premsri, C. Namwat, M. de Souza, E. Adams, M. Benenson, S. Gurunathan, J. Tartaglia, J.G. McNeil, D.P. Francis, D. Stablein, D.L. Birx, S. Chunsuttiwat, C. Khamboonruang, P. Thongcharoen, M.L. Robb, N.L. Michael, P. Kunasol, and J.H. Kim Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand N. Engl. J. Med. 361 2009 2209 2220
45. J.M. Rudolph, N. Eickel, C. Haller, M. Schindler, and O.T. Fackler Inhibition of T-cell receptor-induced actin remodeling and relocalization of Lck are evolutionarily conserved activities of lentiviral Nef proteins J. Virol. 83 2009 11528 11539
46. E. Sinclair, P. Barbosa, and M.B. Feinberg The nef gene products of both simian and human immunodeficiency viruses enhance virus infectivity and are functionally interchangeable J. Virol. 71 1997 3641 3651 (Pubitemid 27172376)
47. B. Stolp, M. Reichman-Fried, L. Abraham, X. Pan, S.I. Giese, S. Hannemann, P. Goulimari, E. Raz, R. Grosse, and O.T. Fackler HIV-1 Nef interferes with host cell motility by deregulation of Cofilin Cell Host Microbe 6 2009 174 186
48. O. Takeuchi, and S. Akira Pattern recognition receptors and inflammation Cell 140 2010 805 820
49. N. Tatsis, M.O. Lasaro, S.W. Lin, L.H. Haut, Z.Q. Xiang, D. Zhou, L. Dimenna, H. Li, A. Bian, S. Abdulla, Y. Li, W. Giles-Davis, J. Engram, S.J. Ratcliffe, G. Silvestri, H.C. Ertl, and M.R. Betts Adenovirus vector-induced immune responses in nonhuman primates: responses to prime boost regimens J. Immunol. 182 2009 6587 6599
50. P. Tiollais, and Z. Chen The hepatitis B Pathol. Biol. (Paris) 58 2010 243 244
51. F.W. van Ginkel, R.J. Jackson, Y. Yuki, and J.R. McGhee Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues J. Immunol. 165 2000 4778 4782
52. P. von Hoegen Synthetic biomimetic supra molecular biovector (SMBV) particles for nasal vaccine delivery Adv. Drug Deliv. Rev. 51 2001 113 125 (Pubitemid 32763076)